Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MCK with free AI briefings, catalyst countdowns, and dilution alerts.

MCK · MCKESSON CORP

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$6.5B Cash on Hand
CF+ Cash Runway
Follow MCK by email Get an email when MCK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MCK, unsubscribe in one click. Privacy

📣 What MCK Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus

Also used in these trials (approved or third-party drugs, not MCK's own candidates): Dronedarone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MCK holds $6.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MCK files for a raise →

👥 Who Owns MCK

Insiders 0.1% Institutions (2760 holders) 95.8% Public and other holders 4.1%
HolderTypeShares% of sharesAs of
Vanguard Capital Management Institution (13G, 5%+) 9,180,981 7.95% 2026-03-31
Britt J. Vitalone
EVP & CFO
Insider 22,506 0.02% 2026-05-23
Ramesh (NMN) Srinivasan
EVP and Chief Strategy Officer · +368 options
Insider 11,959 0.01% 2026-08-01
Brian S. Tyler
Chief Executive Officer, Director
Insider 6,135 0.01% 2026-07-07
LeAnn B Smith
EVP & Chief HR Officer
Insider 4,798 0.00% 2026-06-01
Francisco Fraga
EVP, CIO and CTO
Insider 4,415 0.00% 2026-11-05
Michele Lau
EVP and Chief Legal Officer · +725 options
Insider 3,386 0.00% 2026-05-26
Thomas L Rodgers
EVP, Chief Strategy & BDO
Insider 2,268 0.00% 2026-06-01
Dominic J Caruso
Director
Insider 927 0.00% 2026-07-22
Kathleen Wilson-Thompson
Director
Insider 578 0.00% 2026-07-22
Maria Martinez
Director
Insider 578 0.00% 2026-07-22
Napoleon B JR Rutledge
SVP, Controller & CAO
Insider 521 0.00% 2026-09-08

Share count 115,456,664 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MCK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MCK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.